SCHEMBL18705162

SCHEMBL18705162

CC(C)N1CCC2(CCN(C(=O)OC(C)(C)C)C2)C1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SCD5 Q86SK9 1/20 0.46
CYP11B2 P19099 1/20 0.45
ACACB O00763 5/20 0.44
CYP2D6 P10635 4/20 0.44
CYP2C9 P11712 3/20 0.44
CYP1A2 P05177 3/20 0.44
ALDH1A1 P00352 2/20 0.44
GPR183 P32249 1/20 0.42
TSHR P16473 3/20 0.41
CYP2C19 P33261 2/20 0.41
HIF1A Q16665 1/20 0.41
USP2 O75604 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
HDAC2 Q92769 2/20 0.40
HDAC1 Q13547 1/20 0.40
CYP3A4 P08684 2/20 0.39
HRH3 Q9Y5N1 1/20 0.39
ALOX15 P16050 1/20 0.38
RECQL P46063 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18705176 0.93 CYP2C9 (0.50) SCD5CYP11B2ACACBCYP2D6CYP2C9
SCHEMBL18705174 0.93 CYP1A2 (0.50) SCD5CYP11B2ACACBCYP2D6CYP2C9
SCHEMBL3332085 0.93 USP2 (0.45) SCD5CYP11B2ACACBCYP2D6CYP2C9
SCHEMBL18705168 0.93 CYP11B2 (0.46) SCD5CYP11B2ACACBCYP2D6CYP2C9
SCHEMBL18374882 0.93 CYP11B2 (0.48) SCD5CYP11B2ACACBCYP2D6CYP2C9
SCHEMBL18375131 0.91 USP2 (0.46) SCD5CYP11B2ACACBCYP2D6CYP2C9
SCHEMBL12890163 0.91 HRH3 (0.43) SCD5CYP11B2ACACBCYP2D6CYP2C9
SCHEMBL20970989 0.89 SCD5 (0.47) SCD5CYP11B2ACACBCYP2D6CYP2C9
SCHEMBL18705175 0.86 USP2 (0.47) CYP2D6CYP2C9CYP1A2TSHRUSP2
SCHEMBL18705183 0.86 CYP1A2 (0.48) SCD5CYP11B2ACACBCYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220362396-A1 AMINO-PYRAZINECARBOXAMIDE COMPOUNDS, CONJUGATES, AND USES THEREOF SILVERBACK THERAPEUTICS, INC. 2022-11-17 US disclosed
US-11168090-B2 Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2021-11-09 US disclosed
WO-2021102332-A1 TGFBETAR2 INHIBITOR-LRRC15 ANTIBODY CONJUGATES AND USES THEREOF SILVERBACK THERAPEUTICS, INC. (US) 2021-05-27 WO disclosed
US-20200055860-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC 2020-02-20 US disclosed
US-10174027-B2 Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2019-01-08 US disclosed
US-10023570-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2018-07-17 US disclosed
US-10023570-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2018-07-17 US disclosed
US-20180186791-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-07-05 US disclosed
US-20180186790-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-07-05 US disclosed
US-20180186790-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-07-05 US disclosed
US-20180179203-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-06-28 US disclosed
US-20170096425-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA, INC. 2017-04-06 US disclosed
US-20170096425-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA, INC. 2017-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10174027-B2 Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors RET, ROR1, BRAF SCD5 4793/4885CYP11B2 2621/4885ACACB 4822/4885
US-20170096425-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF SCD5 4793/4885CYP11B2 2621/4885ACACB 4822/4885
US-20200055860-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, ROR1 SCD5 4681/4885CYP11B2 2773/4885ACACB 4799/4885
US-20180186790-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF SCD5 4793/4885CYP11B2 2621/4885ACACB 4822/4885
US-20180186791-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF SCD5 4793/4885CYP11B2 2621/4885ACACB 4822/4885
US-20180179203-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF SCD5 4793/4885CYP11B2 2621/4885ACACB 4822/4885
US-20220362396-A1 AMINO-PYRAZINECARBOXAMIDE COMPOUNDS, CONJUGATES, AND USES THEREOF TGFBR2, SMAD2, ACVR2A SCD5 3325/4885CYP11B2 2781/4885ACACB 476/4885
US-11168090-B2 Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors RET, BRAF, ROR1 SCD5 4670/4885CYP11B2 2694/4885ACACB 4807/4885
US-10023570-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, ROR1, BRAF SCD5 4793/4885CYP11B2 2621/4885ACACB 4822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.